Pfizer signs deal allowing generics to produce COVID pill

On the 16th of November, Pfizer announced a deal with international public health group Medicines Patent Pool (MPP) that will allow generic drug manufacturers to produce and supply its experimental antiviral COVID-19 pill. The licensing agreement will authorise the MPP to grant sub-licenses to qualified drug companies in 95 low and middle-income countries, giving residents access to affordable life-saving treatment.  More…